Janus kinase inhibitor has long-term relief in adolescents with atopic dermatitis
Administration of the Janus kinase (JAK) inhibitor upadacitinib can control the manifestations of moderate to severe atopic dermatitis in adolescents for at least a year and a half
28.10.2024